Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...

Cpf1-endo-recombinase CauR co-edited platform was developed and successfully applied to the glutamate-producing strain ...

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St.

At the height of the COVID-19 pandemic in 2020, Marvin Collins ’22, a bioengineering student, was balancing their Stanford classes from home in Alabama while also helping bioengineering professor ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

Advanced engineered cell therapies require gene editing tools that are both precise and efficient. In recent years, CRISPR-Cas9 has emerged as the gold standard for editing genes with greater ...

CRSP’s main value driver is Casgevy, which was approved for sickle cell disease and β-thalassemia. It’s a one-time ex vivo CRISPR/Cas9 stem‐cell therapy. Unfortunately, Casgevy’s rollout has been slow ...

Beam Therapeutics BEAM is engaged in developing investigational gene therapy candidates that are currently in ...

Cathie Wood’s Ark Invest increased exposure to gene-editing names and autonomous mobility companies while further cutting ...

CRISPR is a gene-editing tool that acts like “molecular scissors,” but using it on cancer is complex. The technology’s biggest impact so far is in research labs, helping scientists understand how ...